Background {#s1}
==========

The first 3 papers of the International College of Neuropsychopharmacology (CINP) guidelines for the treatment of bipolar disorder (BD) consisted of a systematic and exhausting review of the literature concerning the available hard data on treatment options and a description of the major clinical challenges the therapist faces together with the patient and his/her family.

The workgroup developed a precise experimental algorithm and a clinical guideline for the treatment of BD, but it is obvious that these products are far from perfect. In fact there are a significant number of issues and needs that were not addressed due to a lack of evidence-based data. Suboptimal treatment and management, however, puts the patients at a higher risk for an adverse outcome with more residual symptoms and higher disability.

This is of utmost importance, since BD is a rather common and complex mental disorder accompanied by significant morbidity and mortality, including a high rate of suicide, while it is obvious that the treatment needs are not fully met by currently available pharmacotherapies and psychosocial interventions of any kind. The problem is further complicated by the poor adherence to treatment that many patients show and the somatic comorbidities that in some cases are adverse effects of medication.

The current paper is the fourth and last of the initiative to develop CINP guidelines for the treatment of BD and summarizes the experience gained from the whole project. It identifies the unmet needs and makes suggestions for future research and the way of dealing with specific issues in BD.

1. Unmet Needs Identified in the Literature (Summarized in [Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}) {#s2}
============================================================================================================================

Diagnosis {#s3}
---------

The first and maybe biggest problem in the management of BD is the difficulty in making early correct diagnosis ([@CIT0046]; [@CIT0045]; [@CIT0035]; [@CIT0056]). In a majority of patients the first episode is depressive, and thus they receive the diagnosis of unipolar depression and they are mistreated with antidepressant monotherapy ([@CIT0073]). It has been reported that as many as 70% of BD patients failed to receive a correct diagnosis in the 1-year period following the initial episode, and in approximately 35% of them the correct diagnosis has been made only after 10 years had passed ([@CIT0046]) Additionally, up to 70% of BD patients but especially bipolar spectrum patients often go unrecognized and undiagnosed, and thus remain untreated or inappropriately treated ([@CIT0035]; [@CIT0026]; [@CIT0042]). Since BD patients are most often misdiagnosed as suffering from unipolar depression or some type of personality disorder, they are frequently treated with antidepressants only or an inappropriate type of psychotherapy for prolonged periods of time.

###### 

Unmet Needs in the Treatment of BD Patients Identified in the Literature

  ------------------------------------------------------------------------------------------------------------------------------------------
  Diagnosis char=\"12\"
  • Early correct diagnosis
  • Recognition and treatment of somatic health problems
  Efficacy and effectiveness of therapeutic options
  • Only 2--3 agents are efficacious across all phases
  • The definition of 'mood stabilizer' is problematic
  • Combining treatments is usually necessary to achieve an acceptable level of efficacy
  • Research so far neglects outcomes like disability, quality of life, burden, and economic issues
  • Limited data on treatments for acute bipolar depression
  • Lack of access to specialized care services
  Gender
  • Little research on gender issues
  • There are some data suggesting that gender is related to different clinical pictures, adverse events profile and to different outcomes
  • Issues related to female physiology and reproduction, especially pregnancy and breast feeding
  Unmet needs: the therapists' point of view
  • Education and support for patients and families
  • Earlier referral to specialist care
  • Improved effectiveness and patient adherence
  • A minority of therapists adheres to evidence-based standards
  • There is an unmet need for the continuous education of professionals
  Unmet needs: the patients' and caregivers' point of view
  • Clinical research never focuses on the unmet needs as the patients conceive them
  • The generalizability of research data to the real-world patient is unknown
  • Burden of caregivers of patients
  Adherence to treatment
  • Psychoeducation is not routinely applied at the earlier stages
  • Empowerment of service users is not the standard
  ------------------------------------------------------------------------------------------------------------------------------------------

###### 

Unmet Needs in the Treatment of BD Patients As Identified During the Process of Guideline Development

  ------------------------------------------------------------------------------------------------------
  Fragmentation of BD as a disorder char=\"12\"
  • Research does not consider BD as a single disorder but as a sequence of largely independent phases
  • Almost impossible to reliably transform the available data into a longitudinal treatment strategy
  Unsatisfactory design of RCTs
  • Scales do not cover the full symptomatology of BD
  • Recognition and reporting of diagnostic criteria and specifiers is problematic
  • Duration too short for acute mania and acute bipolar depression studies
  • Duration of the continuation phase too short before entering the maintenance phase
  • Use of enriched samples almost in all maintenance studies
  • Research on substance and alcohol abuse and medical comorbidities is insufficient
  Focus on more realistic outcomes
  • General impairment and disability
  • Neurocognitive function
  • Social and occupational functioning
  • Quality of life
  Limited data concerning combination treatment and high dosages
  Incomplete results reporting
  • Core symptoms of mania or depression
  • Mixed features
  • Data exist mostly on the manic but not the depressive component of mixed episodes
  • Psychotic symptoms
  • Rapid cycling
  • Incomplete descriptive statistics
  Reporting of the results
  • Inconsistent way of reporting
  • Often different study samples sizes are reported in different documents concerning the same study
  • Last Observation Carried Forward vs Mixed-Effect Model Repeated Measure
  ------------------------------------------------------------------------------------------------------

This problem may persist until the day psychiatric diagnosis is not exclusively based on clinical phenotypes but on reliable and valid biological markers that can be utilized for precise diagnostic differentiation and treatment planning. Of all mental disorders, BD is the one that will probably benefit the most from the introduction of reliable and valid biological markers to our diagnostic armamentarium.

Additionally, physical health problems, especially in bipolar spectrum patients, are underrecognized and undertreated ([@CIT0054]). This is probably a consequence of stigma but also of an unhealthy lifestyle, poor treatment adherence, and only irregular contacts with health care services.

Efficacy and Effectiveness of Therapeutic Options {#s4}
-------------------------------------------------

All authors agree that only 2 to 3 agents have some efficacy across all phases, and no single pharmacotherapy is currently achieving remission in a satisfactory proportion of BD patients both across all phases and in the long term. Acute episodes comprise a relatively small time share of the overall illness, but subthreshold or subclinical symptoms dominate the clinical picture for most of the duration of the lives of patients, causing significant impairment, disability, and burden ([@CIT0038], [@CIT0039]; [@CIT0055]). Since no single pharmacologic treatment is likely to achieve all therapeutic objectives, combining treatments is usually necessary to achieve an acceptable quality of life ([@CIT0031]).

The very concept of what constitutes a "mood stabilizer" is under dispute, since there is no agent that is efficacious against all phases and all major clinical features of BD (manic, mixed, and depressive episodes, rapid cycling). Historically, lithium, valproate, and carbamazepine have all been considered to act as mood stabilizers, but today we have to acknowledge that some atypical antipsychotics, namely quetiapine and olanzapine, do also fulfil many criteria of a mood stabilizer. When it comes to clinical usefulness, while antipsychotics may act faster in acute mania and are also definitely efficacious against psychotic features, there are concerns with the safety profile of all agents useful in the treatment of BD, such as metabolic syndrome with antipsychotics, kidney and thyroid issues with lithium.

Almost all the literature concerning the treatment of all phases of BD focuses on reporting changes from baseline in a symptom rating scale and neglects other important aspects, including disability, quality of life, burden, and economic issues. Most researchers agree that currently available treatments are more efficacious in the reduction of symptoms than in the improvement of disability and the overall outcome ([@CIT0006]; [@CIT0013]; [@CIT0027]; [@CIT0050]). This is especially true concerning bipolar depression, which is a rather refractory mental state with high risk for suicide ([@CIT0001]; [@CIT0075]; [@CIT0026], [@CIT0027]) and profound and lasting functional impairment ([@CIT0011]). Residual symptoms may interfere with the ability of the patients to access and benefit from health care but also from the general state welfare ([@CIT0028]). Particularly in those patients with more severe disability, functional decline, and poor quality of life, the overall burden is further increased by a higher mortality from comorbid medical conditions ([@CIT0053]) and suicide ([@CIT0055]). In these cases, the burden is also higher for caregivers, and the increased service utilization leads to a higher overall cost. This is made even worse when discriminatory coverage and reimbursement policies for mental health care are in place as they are in many countries around the world ([@CIT0014]; [@CIT0055]).

It is unfortunate (although the reasons are apparent) that, by far, fewer randomized controlled trials (RCTs) have been conducted on the treatment of acute bipolar depression than for acute mania ([@CIT0033]). The changing composition of the study samples is a developing problem for all RCTs in mental disorders, and it seems that nowadays larger numbers of patients are required to demonstrate a significant effect compared with earlier studies, although the reasons for this are not entirely understood ([@CIT0064]).

Comprehensive managed care comprising of intensive follow-up, psychosocial and psychological treatment, and functional rehabilitation is not easily accessible to patients, even in developed countries. Lack of access to such services probably adversely influences the overall long-term outcome ([@CIT0055]; [@CIT0030]).

Gender {#s5}
------

While it is known that there are gender-specific factors that can influence the treatment and overall management of patients with BD ([@CIT0043]; [@CIT0034]; [@CIT0044]; [@CIT0020]), little research has been conducted in this area. This is important since unmet needs could differ between males and females ([@CIT0020]; [@CIT0055]).

Although the prevalence of BD-I is similar between genders ([@CIT0055]), more females suffer from BD-II ([@CIT0043]) and depressive predominant polarity ([@CIT0058]). In addition, rapid cycling, mixed episodes, and dysphoric mania but also hypothyroidism and personality disorders might be more prevalent in females ([@CIT0051]; [@CIT0003]; [@CIT0038]; [@CIT0025]; [@CIT0055]), while suicidality, psychotic features, and hospitalizations are more frequently seen in males ([@CIT0055]). There is a greater incidence of a childhood history of sexual abuse among female patients ([@CIT0036]), and this is probably true also for adulthood ([@CIT0018]). A history of sexual abuse or the high risk to become a victim might justify nursing the patient in a single-sex environment, although such environments are vanishing. There are some data suggesting a different risk depending on gender comorbid alcohol and substance abuse ([@CIT0034]; [@CIT0025]). As protective factors, female patients with BD less often stay single or are without children and less frequently live alone. They seem to maintain better global functioning compared with male patients with BD ([@CIT0055]).

The most prominent issues with female BD patients are around the reproductive cycle and related physiology. While the influence of the menstrual cycle and menopause on the course of BD is still unclear, there are some research data on the effects of motherhood. It is simply reasonable that in the case of a pregnant patient, multidisciplinary care together with the obstetrician and midwife is mandatory.

The most commonly emerging issues concern unwanted pregnancy ([@CIT0019]). Therefore, bipolar women of childbearing age should receive intense counseling regarding effective contraceptive practice, issues pertaining to interaction of contraceptive pills with medication for BD, and the possible effects of pregnancy and delivery on the course of bipolar illness. Also the treatment options during pregnancy and breast feeding should be discussed along with the psychological and somatic stress of pregnancy and child-rearing, and the effects treatment might have on the fetus depending on the trimester of gestation. Finally, counselling about the genetic risk of BD should be offered also to siblings to enable informed decisions for future pregnancies ([@CIT0060]; [@CIT0017]). In everyday practice, few patients consider the risks related to pregnancy unacceptable, and these should be guided to use effective contraception, which should be considered together with the medication the patient receives to treat BD. Several drugs, for example carbamazepine, oxcarbazepine, lamotrigine, and topiramate, all increase the clearance rate of oral contraceptives, and thus the doses of oral contraceptive for patients taking these medications need to be adjusted and/or other protective strategies need to be implemented as a standard of care.

According to some studies, pregnancy is associated with a reduced overall risk for psychiatric admission ([@CIT0041]) and a lower risk for suicide ([@CIT0002]; [@CIT0048]) and may improve the clinical course of BD ([@CIT0068]; [@CIT0032]), but there are also reports of the opposite ([@CIT0010]; [@CIT0024]). On the other hand, there is a broad consensus that the postpartum period confers the greatest risk for exacerbation of BD (usually within 90 days) ([@CIT0022]; [@CIT0012]; [@CIT0021]; [@CIT0041]; [@CIT0067]; [@CIT0043]; [@CIT0010]; [@CIT0024]).

Besides the issues concerning the reproductive cycle, female patients appear to be at greater risk for a number of medication adverse effects, including weight gain ([@CIT0023]; [@CIT0063]) and extreme obesity ([@CIT0024]) and decrease in bone mineral density as a result of prolonged hyperprolactinemia ([@CIT0078]), which could also cause a hypogonadal state ([@CIT0024]).

The Therapists' Point of View {#s6}
-----------------------------

There is not much data concerning the point of view of psychiatrists and of therapists in general on the unmet needs in the treatment of BD patients.

One study reported that psychiatrists in the UK and US consider education and support for patients and families as well as earlier referral to specialist care as the highest ranked needs at entry into care. On the other hand, they thought that during treatment of acute episodes and also during the long-term management, the most important needs were improved effectiveness of treatments and patient adherence in addition to improved long-term safety in the maintenance phase. These mental health professionals ranked patients with comorbid alcohol and/or substance use disorders as having the highest level of unmet need, followed by rapid-cycling patients ([@CIT0016]).

A second study reported that clinicians were not adherent to evidence-based practice and that their clinical practice was not consistent with the results of clinical trial data or current guideline recommendations. Additionally, there seems to be an unmet need for education to enable psychiatrists to differentiate between unipolar and bipolar depression, to identify the risk of treatment-emergent mood disorders with the use of antidepressants, and to effectively manage patients at risk for BD-I. It is surprising that only one-half of the respondents thought that treatment guidelines should be important in their everyday clinical practice, and additionally they also reported that clinical trial results were the least influential. Furthermore, only one-third of the respondents were familiar with large practical clinical trials and scientific associations, organizations, and other bodies relating to BD ([@CIT0029]). Overall, the findings clearly indicate that many clinicians are not well informed about the evidence base of their treatment choices for BD patients, especially for depressive symptoms, and they are also not well trained concerning the clinical assessment and management of BD ([@CIT0033]). Guidelines to provide comprehensive introductory information, suggestions, and resources for caregivers have been developed to assist them to formulate treatment strategies ranging from a stepped-care approach to supporting caregivers, ranging from basic information and pamphlets to brief training courses and specialized family or caregiver interventions based on need and accessibility ([@CIT0009]).

The Patients' and Caregivers' Point of View {#s7}
-------------------------------------------

It is well known that different "stakeholders" emphasize different unmet needs, and therefore the point of view of patients and caregivers might vary considerably from the point of view of mental health professionals ([@CIT0015]). What may contribute to poor adherence is the fact that clinical research hardly focuses on the unmet needs as the patients perceive them and therefore, at least to some extent, real world needs are not addressed ([@CIT0005]). Even more, it is not known to what extend clinical trials data apply to those patients who are not eligible to be included in standardized controlled research, because they suffer from multiple comorbidities or have shown refractoriness to treatment in the past ([@CIT0076]; [@CIT0008]; [@CIT0070]; [@CIT0077]; [@CIT0066]; [@CIT0007]). There is also profound discrepancy between the interpretation by mental health professionals of the evidence base for treatments in BD and patient perception of the relative effectiveness of different treatment options ([@CIT0049]).

If the real outcome of mental disease is what patients report concerning their quality of life, research gives a grim picture with patients with severe mental illness reporting dissatisfaction with their social functioning and general health and unmet needs concerning case management services, social and recreational activities, and vocational rehabilitation ([@CIT0004]).

Caregivers of patients with BD may experience a different quality of burden than is seen with other illnesses, and it is definitely more severe compared with the burden of caregivers of patients with unipolar depression. However, there is not enough research data on this issue, which is largely neglected ([@CIT0062]). Conceptualizing the burden of a bipolar caregiver in a conventional medical framework may not focus enough on important issues or on cultural and social issues as well as on the objective and subjective aspects of burden. An important fact is that burden to caregivers is associated with caregiver depression, which conversely affects patient recovery by adding stress to the home environment. It is also associated with high levels of expressed emotion, including critical, hostile, or over-involved attitudes. It is reasonable to assume that it is not possible to ameliorate service provision without a better understanding of caregiver burden and the means to measure and target it ([@CIT0059]).

Adherence to Treatment {#s8}
----------------------

Poor treatment adherence is a major problem in mental health care, and especially in BD it is associated with poor outcome ([@CIT0040]; [@CIT0006]). Depending on definition and setting, it has been reported that between one- and two-thirds of BD patients are noncompliant with treatment ([@CIT0037]; [@CIT0040]; [@CIT0057]). Adverse events are one of the reasons patients are often unwilling to continue medication treatment for prolonged periods of time. Some might also wish to continue to have the experience of manic or especially of hypomanic episodes, which are particularly pleasant. Psychoeducation and collaborating with patients and caregivers enables patients to be active participants in the management process, and this is believed to improve treatment adherence ([@CIT0065]). It is interesting to note that both patients and their families often seemed to lack a thorough understanding of disease management goals and the need for follow-up care ([@CIT0046]).

Therefore, there seems to be a clear need for more empowerment of patients and their caregivers. Currently they appear less than optimally informed concerning the need and benefits of continuation treatment and care, with the result of high rates of poor treatment adherence.

2. Unmet Needs Identified by the CINP Guidelines Project {#s9}
========================================================

As described and reported in the previous papers of the CINP guidelines, the workgroup synthesized and analyzed the accessible data on the efficacy of existing treatment options for BD. The essential result was a large table of efficacy data for each treatment option across different phases of the illness and considering specific clinical features. The analysis, classification, and tabulation of the results revealed a number of important problems and unmet needs as well as areas that should be the focus of research in the future.

Fragmentation of BD As a Disorder {#s10}
---------------------------------

A major problem of the literature is that it is almost impossible to reliably assemble the available data in a longitudinal treatment strategy that would take into consideration the present phase but also the psychiatric history and possible future development. That is, the data do not consider BD as a single disorder but as separate and literally independent phases. At the guidelines but also the clinical level, it creates a very important dilemma. What should the decision for the maintenance treatment be in case the patient was treated (and responded to) with a treatment with no data concerning the long-term prophylactic treatment, or even worse with negative data concerning the assumed possible future of his or her mental health? For example, a patient has responded favorably to haloperidol during an acute manic episode, but since the patient's history indicates that the overwhelming majority of the mood episodes were depressive episodes (depressive predominant polarity), it is fair to assume that these episodes will continue to be frequent. In such a case, the therapist is left with a dilemma: should he or she add an agent with proven preventive efficacy against depressive episodes, for example quetiapine, and apply combination treatment, or should he or she change to monotherapy with an agent with proven prophylactic efficacy against both poles? The answer is not apparent and different opinions do exist, especially since almost all maintenance studies include enriched samples, that is samples of patients who responded during the acute phase specifically to the agent under research. Especially in cases of partial or poor response to first line treatment, it is unknown which would be the best next option. Switching might prolong suffering while adjunctive treatment will result in polypharmacy.

Future research should focus on these problems and provide specific answers. Ideally, all treatment options should be tested against all phases and clinical features of BD, and those with broader efficacy should receive priority in the use. Of course safety and tolerability issues might additionally perplex the problem.

Unsatisfactory Design of RCTs {#s11}
-----------------------------

The inclusion of too many scales probably creates severe problems with the completion of RCTs; however, the trials should include those scales that have been proven to be of high importance for everyday clinical practice. In addition, reporting should not only include global measures but inform professionals more specifically which diagnostic features and specifiers of BD responded to a given treatment. However, the total costs of a trial and the feasibility need to be balanced against the research benefits.

In this framework, the design of future clinical trials should take into consideration that outcomes should address issues like mixed features, anxiety, psychotic symptoms, neurocognitive disorder, and disability. Currently there are few data on mixed features in acute bipolar depression, and almost all data on mixed episodes come from acute mania trials. At the same time, the overall design should keep the effort for the patients and the researchers at a minimum by avoiding unnecessary ratings and making RCTs feasible.

An important concern to mention is the duration of the continuation phase before entering the maintenance phase, which is often unacceptably short. This is sometimes the case for acute phase studies and especially for bipolar depression. Since the aripiprazole studies had positive results at week 6 but negative at endpoint, which was week 8 ([@CIT0072]), it is reasonable to suggest that the minimum duration for acute bipolar depression studies should be 8 weeks to capture true and lasting improvement. However, this is not always the case, and at least one agent gained approval with a positive study of only 6 weeks duration ([@CIT0047]).

While the enriched designs inform about the longer term efficacy of an agent if it was effective for an acute phase, they do not provide information about whether or not they have broader spectrum of prophylactic efficacy (i.e., prophylactic efficacy in patients who responded to other agents during acute phase). While many agents that are effective in acute phase appear to provide benefit during the maintenance phase, it is unknown whether this can be generalized to all agents for the maintenance period.

In acute mania, a study duration of 3 weeks appears not adequate; however, most studies utilized this short duration. Probably the best solution would be to utilize a 12-week design both in acute mania and depression RCTs that may allow for assessing both manic and depressive symptoms that often coexist. The use of placebo is acceptable, but ideally a third arm with a comparator would be more informative for assay sensitivity ([@CIT0074]).

Research on substance and alcohol abuse and medical comorbidities should be a specific target of research and probably cannot be incorporated in the frame of the standard RCTs. Large observational studies may be needed to supplement controlled trials.

Focus on More Realistic Outcomes {#s12}
--------------------------------

Almost all the RCTs are industry sponsored, and therefore their primary aim is to obtain labelling for the product. Thus, the primary outcome is always the change in the total score of a scale that measures the symptoms of the acute phase (YMRS, MRS, MADRS, or the HAM-D), while the CGI or the PANSS are included as secondary outcomes. Rates of response and remission are almost always included as secondary outcomes. Relapse into a mood episode is the most usual primary outcome for maintenance studies.

It is very rare that measurements of general impairment, neurocognitive function, social and occupational quality of life, etc. are utilized. Although the currently used outcomes serve the purpose to test whether the agent under consideration is efficacious or not, they fail to capture aspects of treatment that are equally clinically relevant and of high importance for the everyday clinical practice.

Limited Data Concerning Combination Treatment and High Dosages {#s13}
--------------------------------------------------------------

While in everyday clinical practice polypharmacy is the rule rather than the exception, the research data in support of most combination options are weak or absent. This is also the case with the use of high dosages, which is often everyday clinical practice.

Incomplete Results Reporting {#s14}
----------------------------

Although the data are often available, the authors and the manufacturers decide not to report them. Examples include the effect of treatment options on the core symptoms of mania or depression and on mixed features, psychotic symptoms, rapid cycling, etc. Often only *P* values are reported without means and SDs and at other times the opposite happens, thus adding confusion. In many instances, total scale scores with problematic interpretation (e.g., total PANSS score) are reported without a more detailed subanalysis. Sometimes the data are not available for the entire study sample and thus different sample sizes apply for each outcome; however, this is not always made transparent. It is unacceptable that usually in mixed episodes only the effect of the treatment modality on the manic component is reported but the effect on the depressive component is missing.

It is desirable for the raw data to be released and accessible for the scientific community. Much advancement in our knowledge and ability to treat BD patients better may arise not from new and expensive research but from simply exhaustively analyzing existing data. The release of the raw data will also remove publication bias and improve the reliability of conclusions.

Reporting of the Results {#s15}
------------------------

The overall impression from the review of the literature is that the results are reported in a nonhomogenous way and although some kind of a template exists, it is not always possible to detect and extract all details. This is a particular problem when extracting data to perform meta-analysis. Important details are often missing, for example, the score on the positive subscale of the PANSS, while others that are less important exist, for example, the PANSS total score. In most instances, a Last Observation Carried Forward approach is utilized while in a minority the Mixed-Effect Model Repeated Measure is used. In some cases the results are reported selectively from either model. Each model/approach has its advantages and disadvantages ([@CIT0069]). It is also dubious that often different numbers for study samples are found in different publications of the same original study. It is also important that reports fulfil the CONSORT requirements.

3. Recommendations for Future Research Policies (Summarized in [Table 3](#T3){ref-type="table"}) {#s16}
================================================================================================

Availability of the Raw Data {#s17}
----------------------------

The wealth of data that has been accumulated but not exhaustively analyzed is huge. The full release of these data will not only provide us with answers to a number of questions but it will also eliminate much of the publication bias that makes conclusions difficult. One of the most important questions that, if not answered, then at least could lead to a much better understanding is which (if any) baseline clinical characteristics predict response to specific treatments.

###### 

Recommendations of the Workgroup for Further Research

  ----------------------------------------------------------------------------------------
  Availability of the raw data char=\"12\"
  Study design
  • Study any acute mood episode with the same broad protocol
  • Anxiety and psychotic symptoms should also be assessed
  • Assessment of neurocognitive function in long-term studies
  • Assessment of disability and social and occupational functioning and quality of life
  • Adequate duration of studies
  • Separate studies of both enriched and nonenriched samples in maintenance studies
  • Studies focusing on mixed depression
  Proposed template for a standardized reporting of the results (see appendix)
  ----------------------------------------------------------------------------------------

Since for the vast majority of treatment options the patents have expired, there is no practical reason for the industry to justify the withholding of the data except of a possible loss of face if a previously biased reporting becomes apparent. However, even in the case of those agents still under patent, the benefit for the public health should be considered as more important than any supposed commercial interest. In any case, this should be considered to be a matter of transparency.

Study Design {#s18}
------------

Future RCTs conducted for licensing purposes will probably need to consider any acute mood episode in a similar way. Since pure episodes of either pole are not the rule but rather the exception and with the "mixed features" specifier in place by the DSM-5, it is important to assess the presence of depressive symptoms in acute mania and manic symptoms in acute bipolar depression. In either case, anxiety and psychotic symptoms should also be assessed. This means that in all RCTs, YMRS or MRS, MADRS or HAM-D, HAM-A, and PANSS need to be included. It is desirable although difficult to include regular assessments of neurocognitive function especially in maintenance studies. For long-term studies, the assessment of disability and especially of social and occupational functioning and quality of life should be mandatory.

Template for a Standardized Reporting of the Results {#s19}
----------------------------------------------------

As already mentioned, there is a need to standardize the reporting of RCT results and make sure that not only all important results are released but also in a manner that adds to our understanding of the treatment of BD and also makes further analysis possible. Such standardization will also increase the reliability of the reports and eliminate the reporting of slightly different results in different articles concerning the same study. A proposed template for the reporting of RCT results is shown in the appendix. The template is laid out for 2 arms (agent vs placebo), and in cases of different design (no placebo or 3-arm design) it should be modified accordingly. It is suggested that both the results according to Last Observation Carried Forward and Mixed-Effect Model Repeated Measure should be reported. Also it seems important to have a standardized list of adverse events and procedure how to capture them, so that it will be easy to compare across studies. The template presented in the appendix is a convenient summary that can be used as a guide as to which results could be of importance and should be reported.

4. Discussion {#s20}
=============

It is clear that unmet clinical needs exist for all phases of BD. While the review of the literature suggests that early and reliable diagnosis as well as gaps in the education of patients and their families could constitute the biggest unmet needs in the area of BD, the experience from the analysis of the existing evidence identified additional important problems concerning the available knowledge and the way research is carried out.

One important conclusion is that the existing data may already provide answers to a number of clinical questions, including the specific treatment of subgroups of patients. However, relevant analyses have not been carried out and the raw data are not released. Taking full advantage of the data already gathered might have an impact that will have a greater impact in the short term than any new research. There is a pressing need and it is for the benefit of public health that the data should be released and such analyses are carried out.

On the other hand, it is also evident that a standardized design for future RCTs is desirable that reflects the complex clinical picture of BD, with the simultaneous rating of manic, depressive, and psychotic symptoms during all phases of the disorder. The design should be standardized to avoid biases and uncertainties that are frequent because of the current way things are carried out.

A standardized way of reporting the results also seems necessary, since currently only a small and often patchy part of the results is available. It is not unusual that different documents that all report the results of the same trial include slightly different figures. This raises the issue of overall reliability on the current mode of scientific reporting. Besides reporting and appraising the evidence, guidelines should also be educational and promote good practice. The authors hope that the CINP guidelines on BD will have a positive impact on the methodology of future patient-orientated research.
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